Michael Seckler
Chief Executive Officer bei EVOME MEDICAL TECHNOLOGIES INC.
Vermögen: - $ am 31.03.2024
Profil
Michael D.
Seckler is currently the Chief Executive Officer & Director at Evome Medical Technologies, Inc. He is also a Director at GLyPharma Therapeutic, Inc. Previously, he held the position of Vice President-Global Marketing at Ferring Pharmaceuticals, Inc. from 2017 to 2019.
From 2020 to 2023, he served as the Chief Operating Officer at FerGene, Inc. Mr. Seckler completed his undergraduate degree and MBA at The Pennsylvania State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 24.07.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Michael Seckler
| Unternehmen | Position | Beginn |
|---|---|---|
| EVOME MEDICAL TECHNOLOGIES INC. | Chief Executive Officer | 13.06.2023 |
GLyPharma Therapeutic, Inc.
 GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Director/Board Member | - |
Ehemalige bekannte Positionen von Michael Seckler
| Unternehmen | Position | Ende |
|---|---|---|
FerGene, Inc.
 FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Chief Operating Officer | 01.05.2023 |
Ferring Pharmaceuticals, Inc.
 Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Sales & Marketing | 01.12.2019 |
Ausbildung von Michael Seckler
| The Pennsylvania State University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| EVOME MEDICAL TECHNOLOGIES INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Ferring Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Health Technology |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Health Technology |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Health Technology |
